Encouraging results from the first proof-of-concept study for adenovirus infection support continued clinical development of CMX001 as a first-in-class broad-spectrum antiviral for prevention of double-stranded DNA viral infections DURHAM, N.C., Aug. 14, 2013 -- Chimerix, Inc. , a biopharmaceutical company developing novel, oral antivirals in areas ... (more)
http://www.drugs.com/clinical_trials/chimerix-announces-top-line-data-cmx001-phase-2-adenovirus-study-15963.html?
http://www.drugs.com/clinical_trials/chimerix-announces-top-line-data-cmx001-phase-2-adenovirus-study-15963.html?
No comments:
Post a Comment